Genomic DNA at cardiometabolic loci

Genomic DNA at cardiometabolic loci refers to the specific sequences and regulatory regions of the human genome that influence metabolic and cardiovascular health. These loci are identified primarily through genome-wide association studies (GWAS) and include genes such as PCSK9, ANGPTL3, and LPA, which regulate cholesterol and triglyceride levels (Source: NIH, 2022). While traditional drugs target the proteins encoded by these genes, emerging therapies like CRISPR-based base editing directly target the genomic DNA at these specific loci to permanently lower disease-causing proteins (Source: Nature Medicine, 2023). This approach represents a shift toward 'genetic medicines' for common chronic diseases like atherosclerosis and type 2 diabetes. Because this 'target' is a collection of diverse genetic sites rather than a single molecule, it is considered a therapeutic category rather than a single drug target. Safety concerns include potential off-target editing and the long-term consequences of permanent genomic alteration (Source: Science, 2021). The biological function of these loci involves the complex regulation of lipid metabolism, glucose homeostasis, and inflammatory pathways. Therapeutic success at these loci depends on the precision of the delivery system and the specificity of the genetic modification tool.

Other names

Cardiometabolic risk lociCardiometabolic GWAS lociMetabolic syndrome associated genomic regionsCardiovascular disease associated DNA sequences

Base editing or gene editing (e.g., CRISPR/Cas9) to permanently modify specific DNA sequences at these loci to silence or alter the expression of genes involved in metabolic pathways.